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Abstract. Endogenous transmethylation processes proceed via formaldehyde. Endogenous formaldehyde can 
be found in special bounded forms in animal tissues. The aim was to find non-invasive methods to help estab-
lish an early diagnosis of prostate cancer processes, and to search for a reliable examination repertoire to pre-
dict metastasis based on genomic hypomethylation that can be found in tumors. Fifty-eight age-matched pa-
tients suffering from prostate cancer and 26 healthy volunteers were enrolled in the study. Biochip technique 
was applied to quantify serum interleukins and growth factors. OPCL method served to determine mobilized 
formaldehyde, and fluorometric methods were applied to measure Zn- and free protoporphyrin concentra-
tions in erythrocytes. Spectrophotometric measurements were carried out to evaluate redox homeostasis in 
plasma. There were no significant differences in most measured laboratory and immune parameters at differ-
ent early stages of prostate cancer; at the same time, erythrocyte parameters, especially immobilized formal-
dehyde determination, were promising. The authors assume that hypomethylation detection in erythrocytes 
might become a predictive factor in the diagnostic panel in the near future. (doi: 10.5562/cca1748) 
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INTRODUCTION 
A large number of people, mostly around the age of 50, 
suffer from prostate cancer in the world, and so also in 
Hungary. In Hungary, 4500 prostate cancer patients and 
1400 deaths were registered in 2009. According to a 
2008 statistical report, prostate cancer is the second 
cancer-related cause of death for men in the United 
States.1 
Prostate cancer is silent and has no early warning 
symptoms. Extensive use of serum prostate specific 
antigen (PSA) testing has been increasingly reported at 
earlier stages, although false negative or positive diag-
noses can occur. 
Treating prostate cancer is a major challenge to-
day. In case of localized cancer tissue in a patient in 
good condition with more than 10 years of life expec-
tancy, radical surgery is the treatment of choice. Bones 
are the predominant sites of distant metastases caused 
by prostate cancer.2 It is still not possible to determine 
which patients are at high risk of tumor recurrence after 
primary local therapy and will not benefit from surgery. 
No more promising indicators are available to distin-
guish between surgically curable and oncologically 
treatable prostate cancers. No optimal factor has so far 
been found for the prognosis, although several authors 
maintain that IL-6, IL-10, TNF-alpha and VEGF are 
increased and IL-2 is decreased in case of the appear-
ance of metastasis in glands and bones. Also, a high titer 
of C-reactive protein is associated with early tumor 
recurrence and poor survival in hormone independent 
tumor occurrences.3–6 Increased expression of ID-1 
protein regulates the differentiation of osteoblasts and 
negatively regulates the expression of TNF-beta, which 
is significantly associated with bone metastasis and 
shorter survival of prostate cancer patients.7–9 
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Changes in transmethylation ability and genomic 
hypomethylation have been verified in both human and 
animal tumors and experimental evidence suggests their 
key roles in tumorigenesis.10–12 
It was earlier clarified that transmethylation 
processes occur via formaldehyde, mobilized methyl 
group and not via methyl cation in life systems.13 
In our previous studies, significant changes were 
observed in erythrocyte function in colectomized pa-
tients suffering from colon cancer. In adult colecto-
mized patients after 5–10 years of colectomy without 
metastasis, erythrocyte mobilized formaldehyde was 
significantly lower than in controls. At the same time, 
protoporphyrin concentration was low in patients with-
out metastasis, when the diagnosis before operation was 
Dukes C. HbA1c level correlated significantly with 
induced free radical level and decreased the antioxidant 
status of erythrocytes.14 
Explanation of the connection between concentra-
tion changes of formaldehyde and protoporphyrin is that 
arginine (38), methionine (65) and lysine (72) near 
methionine (80) are methylated and thereby coordinated 
towards the central iron of heme. Consequently, when 
the transmethylation activity is normal, the hemoglobin 
structure is optimal.15 
Salnikow and Zhitkovich found that genetic and 
epigenetic mechanisms in metal carcinogenesis and 
cocarcinogenes depend on nickel, arsenic, and chro-
mium toxicity and that these elements cause hy-
pomethylation.16 In previous examinations, we ob-
served that the element status of erythrocytes in pa-
tients with prostate cancer was significantly changed 
compared to controls in cases of Al (1.90 ± 1.67 vs 
0.537 ± 0.260), Ni (0.722 ± 0.565 vs 0.265 ± 0.195) 
and Pb (0.309 ± 0.301 vs 0.094 ± 0.053). These ion 
concentrations were significantly high in prostate 
cancer patients with PSA > 9 (Ref. 17). At the same 
time, the erythrocyte protoporphyrin concentration 
was very high in prostate cancer similarly to cases of 
gastrointestinal tumors.18 
Although molecular biological examinations give 
excellent information about the stages of prostate cancer 
or metastasis, their clinical applications are very expen-
sive and cannot be widely used. 
Since the changes in bounded formaldehyde, Zn-
protoporphyrin and free protoporphyrin concentrations 
of erythrocytes may be very important indices in tumor 
anemia, we would like to know whether the determina-
tion of transmethylation ability via formaldehyde dime-
done adduct can be a predictive factor for progression of 
prostate tumor in clinical applications. Immune reactivi-
ty was also examined in searching for correlations be-
tween immune parameters, PSA values and transmethy-
lation processes. 
 
MATERIALS AND METHODS 
Materials 
1,1-diphenyl-2-picryl-hydrasyl stable radical and dime-
done were obtained from SIGMA (St. Louis), Silica gel 
80 F254 precoated chromatoplates were purchased from 
Merck (Darmstadt) and all other reagents were from 
Reanal (Budapest). Biochip for the Evidence Biochip 
Array Analyzer was obtained from Randox (Kearneys-
ville). PSA test was from ABBOTT (Princeton) and 
CRP kit from Olympus (Corporate Pkwy). 
 
Patients 
The study included a total of 58 patients with prostate 
cancer, 18 had metastatic prostate cancer and 28 were at 
an early stage. 12 outpatients had negative and 12 had 
positive histological findings with questionable PSA 
values and laboratory parameters. Age range was the 
same in patient groups and 26 healthy volunteers: 69 ± 6 
/ 68 ± 8 years. 
 
Methods 
Blood samples were drawn from the antecubital vein by 
venipuncture into tubes containing Ca citrate. Plasma, 
serum and erythrocyte samples were separated by stan-
dard methods and stored at −20 °C until assayed. He-
moglobin content was adjusted uniformly to 0.01 g ml−1 
for measurements. 
Serum routine laboratory parameters were deter-
mined with a Hitachi 717 Analyzer, using standard 
methods (not shown) of Randox. PSA levels were de-
termined using the Abbott MEIA test, and the concen-
tration of CRP was measured with the Olympus immu-
noturbidimetric test. 
Evidence Biochip Array Analyzer (Randox) was 
employed to quantify serum interleukins: IL-1 alpha and 
beta, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, interfe-
ron-gamma (IFNG), vascular endothelial growth factor 
(VEGF), monocyte chemoattractant protein-1 (MCP-1), 
and epidermal growth factor (EGF) concentrations. 
Formaldehyde in the dimedone adduct form 
(formaldemethone) was identified and determined by 
the chromarographic method. The samples were treated 
with dimedone solution (0.07 % dimedone in methanol) 
(e.g., 0.7 cm3 sample / 0.7 cm3 of dimedone solution). 
This suspension was centrifuged at 1500 g for 10 
minutes at 4 °C. Clear supernatants were used for 
chromatographic separation.19 Overpressured Layer 
Chromatographic separation (OPLC developed by 
OPLC-NIT Co., Ltd., Budapest, Hungary) was carried 
out on TLC silica gel 60 F254 precoated chromatoplates 
using a chloroform-methylenechloride mixture (35/65, 
v/v) for formaldemethone determination. Samples were  
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applied with a NANOMAT sample applicator (CAMAG 
Co., Muttenz, Switzerland). Calibration curves were 
prepared using an authentic substance. For densitometric 
determination, a Shimadzu CS-930 TLC/HPTLC scanner 
(Shimadzu Co., Kyoto, Japan) λ = 265 nm was used. 
Erythrocyte protoporphyrin IX and Zn-proto-
porphyrin were measured by the fluorometric method 
using a Jasco FP 6300 type fluorometer (Jasco Co, Ja-
pan). Simple micro-method was adapted for purification 
of protoporphyrin by Chisolm and coworkers (1975).20 
Excitation wavelength was 405 nm and that of emission 
610 nm. 
The reducing power of the sample was determined 
at 700 nm according to Oyaizu, based on the chemical 
reaction Fe(III)→Fe(II). Increased absorbance indicated 
increased reducing power, which was expressed as as-
corbic acid equivalent (mmol/l eqAS).21 
The hydrogen-donating ability of the sample was 
estimated in the presence of 1,1-diphenyl-2-picrylhyd-
razyl radical according to Hatano et al.22 
Free SH-groups were determined by the Sedlack 
method, based on the Ellmann reaction (1985).23 All 
spectrophotometic methods were carried out with a 
Jasco V 550 spectrophotometer (Jasco Co., Japan). 
One-way ANOVA statistical analysis was applied 
to evaluate the significance between patient groups. 
This study was approved by the Regional and In-
stitutional Committee of Science and Research Ethics, 
Semmelweis University, Permission Number TUKEB 
127/2006. 
 
RESULTS AND DISCUSSION 
Since laboratory diagnosis of prostate cancer is difficult 
at an early stage and prostate specific antigen can re-
main in normal range or be falsely positive, the general-
ly used laboratory parameters do not signal the appear-
ance of the disease. IL-1 alpha, -beta, IL-2, IL-4, IL-6, 
IL-8, IL-10, TNF-alpha, interferon-gamma, vascular 
endothelial growth factor, monocyte chemoattractant 
protein-1 and epidermal growth factor concentrations 
were determined by the biochip technique with an Evi-
dence Biochip Array Analyzer to establish the progres-
sion of tumor process. Table 1 does not show any sig-
nificant differences in most parameters between study 
groups and controls. Levels of cytokines and growth 
factors were low at the early stage of prostate cancer. 
We found concentrations of IL-1 alpha and -beta, IL-10, 
IFNG (60–80 %) below the measurement range. Serum 
PSA correlated with serum IL-6 (r = 0.78) but the other 
markers did not. CRP value was under 5 mg /l in all 
samples and was not related to the measured parame-
ters. When low concentrations of the above mentioned 
parameters are found in the sera of patients with pros-
tate cancer, we can suppose an early stage of cancer. 
Our results show that measurements of cytokines and 
growth factors did not help establish an early diagnosis 
of prostate cancer. It is an interesting fact that the con-
centrations of cytokines and growth factors are signifi-
cantly lower in old men (age range 60–75 years) than in 
younger ones (data not published). 
 




(N = 26) 
early stage 
(N = 28) 
metastatic 
(N = 18) 
 IL-1 alpha / pg ml−1 0.64 ± 0.50 0.10 ± 0.30 0.54 ± 0.42 
 IL-1 beta / pg ml−1                  1.57 ± 1.3 0.80 ± 2.20  1.18 ± 1.60 
 IL-2 / pg ml−1 4.18 ± 2.80 4.70 ± 5.60                   7.80 ± 4.4 
 IL-4 / pg ml−1 4.56 ± 1.84 2.30 ± 5.40  4.70 ± 2.05 
 IL-6 / pg ml−1 1.51 ± 1.34 1.20 ± 2.30    14.2 ± 24.20 
 IL-8 / pg ml−1 25.21 ± 16.16   9.10 ± 16.30  31.20 ± 87.00 
 IL-10 / pg ml−1 1.08 ± 0.69 0.20 ± 0.50  1.54 ± 1.91 
 TNF-alpha / pg ml−1 7.45 ± 4.23 3.00 ± 3.60  3.41 ± 1.65 
 VEGF / pg ml−1 190 ± 150                   183 ± 94  272 ± 116 
 IFNG / pg ml−1 1.78 ± 1.41   0.8 ± 1.50  4.28 ± 4.21 
 MCP1 / pg ml−1 346 ± 158                   306 ± 93  347 ± 171 
 EGF* / pg ml−1                   212 ± 81 66.8 ± 58.3  59.3 ± 40.4 
 CRP / pg ml−1 <5   5.6 ± 12.8  14.4 ± 24.9 
 PSA / pg ml−1 <2 10.66 ± 7.79*        93 ± 120** 
Significance (p < 0.05): control vs *; * vs **. 
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When we examined the plasma redox parameters 
of patients suffering from prostate cancer and healthy 
controls, we observed only moderate alterations. These 
data did not help establish an early diagnosis and follow 
cancer progression unambiguously contrasted to in-
flammatory bowel diseases, where data indicate mod-
erate and serious forms of diseases (Table 2).24 
At the same time, erythrocyte parameters, Zn-
protoporhyrin, free protoporhyrin and bounded HCHO 
in sensitized dimedone reaction, showed enormous 
differences compared to healthy controls not only in 
taxane-treated metastatic but also in histologically nega-
tive and positive patients when cancer was first ob-
served. In particular, bounded formaldehyde in erythro-
cytes showed alterations compared to healthy controls 
and signaled moderate transmethylation ability at an 
early stage. Significant differences in this parameter 
were found between groups. These data showed that 
transmethylation ability was changed in the course of 
cancer progression (Table 3). 
Early research has already drawn attention to the 
alterations in DNA methylation, which play an important 
role in neoplasia.25 DNA hypomethylation leads to ele-
vated mutation rates.26 Nowadays, many review publica-
tions reveal that the most studied mechanisms by epige-
netics are DNA methylation and histone medications, 
stable and reversible alterations to the genome that affect 
gene expression and genome function. The nature and 
role of the mechanisms of promoter hypermethylation 
during carcinogenesis have been studied worldwide; 
however, the mechanism behind one of the earliest epi-
genetic observations in cancer, genome-wide hypome-
thylation, remains unclear.27 Tumor hypermethylation 
predicts poor prognosis in patients with earlier stages of 
prostate cancer, and is commonly found in the plasma 
DNA of patients with castration-resistant prostate can-
cer.28,29 Extensive molecular biological examinations 
help us more and more to understand the mechanism of 
methylation steps, biochemical pathways, key enzyme 
functions and, recently, to apply targeted therapy.30,31 
Researchers are now searching for natural bioactive 
agents, to modify DNA methylation, such as curcumin, 
which has a potent DNA hypomethylation property.32 
On the basis of our earlier and present studies, hy-
pomethylation seems to be a condition of the system, 
which can be improved with methyl donating molecules 
from food ingredients, such as different N-, S-, and  
O- methylated compounds. The exact mechanisms are 
not known, but the effectiveness can be checked by 
laboratory parameters and improved transmethylation 
ability of erythrocytes in cancer patients.18,33 
 
CONCLUSION 
To conclude, we can say that the determination of 
transmethylation ability in erythrocytes and plasma PSA 
levels may constitute a new methodical approach to 
detecting prostate cancer at an early stage, follow its 
progression and apply the most suitable therapy. The 
authors suppose that exhaustion of the system methyl 
donor pool causes hypomethylation in DNA and his-
tone. This fact is reflected in erythrocyte function in 
cancer processes. The found connections can be in con-
Table 2. Plasma redox parameters of oncological treated cancer patients at different stages 
 Patients 
Plasma free SH-group 
(mmol / l) 
Reducing power 
(mmol / l eqAS) 
H-donating ability 
(inhibition %) 
 Healthy control (N = 14) 0.535 ± 0.052 1.320 ± 0.249 53.95 ± 3.42 
 Prostate tumor (histology −) (N = 12)   0.671 ± 0.161* 1.358 ± 0.230   60.26 ± 5.082 
 Prostate tumor (histology +) (N = 12)   0.667 ± 0.086* 1.249 ± 0.226 54.83 ± 9.23 
 Prostate tumor (metastatic) (N = 18)     0.487 ± 0.063** 1.368 ± 0.207 50.41 ± 7.91 
Significance (p < 0.05)  * vs **. 










 Healthy control (N = 14) nd nd      1.52 × 10
−2 ± 1.25 × 10
−3 nv 
 Prostate tumor (histology −) (N = 10) 1282 ± 513* 325 ± 50*     1.06 × 10
−2* ± 1.44×10−3 9.66 ± 5.28* 
 Prostate tumor (histology +) (N = 30) 1043 ± 372*   582 ± 782*   7.830×10
−3** ± 2.56 ×10−3 13.68 ± 21.91* 
 Prostate tumor (metastatic) (N = 18)   1303 ± 3601* 300 ± 64* 1.02 × 10
−3*** ± 2.73 × 10−4     93 ± 120** 
(a) nd - not detected. 
(b) nv - value is in normal range (normal value of PSA is 0.01– 4.00 ng/ml). 
Significance: control vs *;**;***; * vs **; ** vs ***. 
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cord with serious tumor anemia in metastatic carcinoma. 
Although the preliminary results presented in this paper 
are very promising, further studies on a larger number 
of patients have to be carried out to assess the safety and 
reliability of this method. 
 
ABBREVIATIONS 
CRP, C reactive protein; EGF, epidermal growth factor; 
HbA1c, glycated hemoglobin HCHO, formaldehyde; ID-
1, DNA-binding protein inhibitor ID-1 (inhibitor of diffe-
rentiation-1); IFNG, interferon-gamma; IL-1 alpha/beta, 
IL-2, IL-4, IL-6, IL-8, IL-10, interleukins; OPLC, over-
pressure layer chromatography; PSA, prostate-specific 
antigen; TNF-alpha, tumor necrosis factor-alpha. 
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